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ABSTRACT 
Objective: The aim of this study was to prepare and evaluate a pH sensitive ocular in-situ gel of Naproxen, to increase the ocular residence time. 
Methods: pH sensitive in situ gel formulations were prepared using different concentrations of Carbomer CB [0.5%, 0.6%, 0.7%] in combination 
with hydroxypropyl methylcellulose HPMC K40 [0.75%, 1%, 1.5%] or HPMC K100 [0.5%, 0.75%, 1%, 1.5%]. The prepared in situ gels were 
evaluated for appearance, pH, gelling capacity [sol-to-gel transition/in vitro], tonicity, viscosity, in vitro release studies, release kinetic analysis, and 
the selected formulas were subjected to rheological studies, and the finally selected formula was subjected to drug content, FT-IR studies, and ocular 
irritancy tests.  
Results: Increasing the concentration of the carbomer polymer improved the gelling capacity and gelation time, also the higher the viscosity and 
concentration of the hydrophilic HPMC polymer, the higher the viscosity of the formula, which affected the release, gelation capacity and time. The 
overall results showed that formula F10 [CB 0.7%, HPMC K100 0.75%] exhibited excellent pH-triggered in-situ gelation time, sustained the release 
of naproxen for 3 h’ time with a release rate of more than 90%. 
Conclusion: Ocular in situ gel of naproxen offers a potential dosage form to increase the residence time in the ocular cul de sac, decreasing the drug 
drainage, and increasing the effectiveness of the drug.  
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Ocular in-situ forming gels are polymeric dispersions of low 
viscosity, which are liquid upon installation and undergo phase 
transition; spontaneous coagulation in the ocular cul-de-sac to form 
viscoelastic gels [1], in response to the environmental changes [pH, 
temperature, ion exchange] [2]. In situ ocular gels are superior to 
conventional ocular dosage forms [solutions and suspensions] in 
which ocular drainage is the main set back, [3], and even to the new 
dosage forms [inserts] in which some patients find it difficult to 
apply [4in addition to the irritation it may cause [5].  
pH-triggered system show sol-gel transformation when the pH is 
raised by tear fluid to the ocular pH 7.4, most of the pH sensitive 
polymers are acidic polyanions that are of low viscosity when they 
are unionized, but as the pH increases to the body pH, the polymer 
becomes ionized and swells in the presence of water [6]. The pH 
sensitive polymers are either: cellulose acetate phthalate latex which 
is liquid at pH 4.4 and forms a gel at lacrimal fluid pH of 7.2-7.4, or 
polyacrylic acids PAA; such as carbomers, polycarbophil, these 
polymers differ in the degree and type of crosslinking and the type 
of substitution, they gel at pH above their pKa of 6±0.5, or polyvinyl 
acetal diethylamino acetate AEA solutions with has a low viscosity at 
pH 4 and form a hydrogel at neutral pH condition [7]. 
Although PAA are excellent pH sensitive polymers but the amount 
required to form a stiff gel upon instillation in the eye is not easily 
neutralized by the buffering action of tear fluid or may require 
higher PAA concentration that may irritate the ocular tissue; 
therefore, combination PAA with a suitable hydrophilic cellulose 
viscosity-enhancing polymer allows a reduction in the PAA 
concentration without comprising the in situ gelling properties [8], 
and will improve mucoadhesion. Naproxen is a non-steroidal anti-
inflammatory drug NSAID propionic acid derivative; which inhibits 
both Cyclooxygenase enzymes COX 1 and COX 2 [9], which function 
is to promote prostaglandin production; hence, providing both 
analgesic and anti-inflammatory activities and when naproxen at a 
concentration of 0.2% [10], is given topically to the eye surface, it is 
effective in decreasing aqueous levels of proteins and the rate of 
miosis, and the maintenance of mydriasis during cataract surgery. 
Thereby; preventing and controlling ocular inflammation after 
cataract surgery [11, 12]. 
The aim of the study was to prepare ocular in-situ gel of naproxen 
using carbomer as a pH sensitive gelling agent with different 
concentration of a hydrophilic mucoadhesive polymer.  
MATERIALS AND METHODS 
Materials 
Naproxen, hydroxypropyl methylcellulose K40 (HPMC K40), 
hydroxypropyl methylcellulose K100 (HPMC K1000), were obtained 
from Hangzhou Hyper Chemicals Limited, China and Carbomer (CB) 
Carbopol 940 was purchased from HiMedia lab., Pvt Ltd, Mumbai, India 
Methods 
Characterization of naproxen  
1-Differential scanning calorimetry DSC 
Thermal characterization of pure drug was performed with DSC 
[Shimadzu, Japan]. Samples were weighed (2.00±0.5 mg) and placed in 
sealed aluminum pans. The equipment was calibrated with indium. The 
samples were scanned at 200 °C/min from 250 °C to 300 °C. 
2-Solubility measurement of naproxen  
Excess amount of naproxen was sonicated for 10 min with different 
solvents; water, phosphate buffer pH 7.2 and stimulated tear fluid 
STF pH 7.4 (sodium chloride 0.6 gm, bicarbonate sodium 0.20 gm, 
calcium chloride 2H2O 0.008g, one drop of HCL, distilled water to 
100 ml) [13]. These solutions were incubated in a water bath shaker 
(Memmert, Germany) at room temperature for 72 h. The samples 
were then filtered and examined after suitable dilution, 
spectrophotometrically at the maximum wavelength of 330 nm [14]. 
Preparation of naproxen in situ gel  
pH sensitive naproxen in situ gel formulations were prepared 
according to table 1 using different concentration of HPMC K40 or 
HPMC K100 [0.5%, 0.75%, 1%, 1.5%) by heating 70 ml water to 70 
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°C, then HPMC was added slowly with continuous stirring on a hot 
plate [15] Stuart, UK, after complete addition of HPMC, the solution 
was allowed to cool in a refrigerator overnight, to obtain a clear fully 
hydrated dispersion. Then CB (0.5%, 0.6%, 0.7%) was sprinkled [16] 
on the HPMC dispersion slowly with continuous stirring on the 
magnetic stirrer with heating to approximately 70 °C, until the CB 
was fully dispersed. The desired amount of naproxen was dissolved 
in about 30 ml of phosphate buffer 7.2 using the sonicater, until a 
clear drug solution was obtained, this solution was finally added to 
the polymer dispersion with continuous stirring after polymer 
solution cooled and the final volume was made up 100 ml with 
water. The formulation was filtered by passage through a sterile 
membrane filter of pore size of 0.22 μm (Millipore type) into 
previously sterilized final containers which are then sealed to 
exclude microorganism. Preservatives were excluded to avoid 
interaction with the formula ingredients and to avoid irritation to 
the ocular membranes. 
Evaluation parameters of the formulated in-situ gels 
Appearance 
The formulations were observed for general appearance i.e. color, 
and for the presence of suspended particulate matter. The clarity of 
the preparation was checked using against black and white 
background [16, 17].  
pH 
The pH of the formulations was measured using a digital pH meter 
(ATC China). The pH meter probe was immersed in the formulation 
for 5 min. and then the readings were taken [18].  
 
Table 1: Naproxen ocular in situ gel formulas composition expressed as %W/V 
HPMC K100 HPMC K40 Carbomer CB Naproxen Formulation code 
 0.75 0.5 0.2 F1 
 1 0.5 0.2 F2 
 1.5 0.5 0.2 F3 
 0.75 0.6 0.2 F4 
 1 0.6 0.2 F5 
 1.5 0.6 0.2 F6 
 0.75 0.7 0.2 F7 
 1 0.7 0.2 F8 
 1.5 0.7 0.2 F9 
0.75  0.7 0.2 F10 
1  0.7 0.2 F11 
1.5  0.7 0.2 F12 
0.5  0.7 0.2 F13 
 
Gelling capacity [sol-to-gel transition/in vitro] 
All prepared formulations were evaluated for gelling capacity, time 
and viscosity in order to identify the compositions suitable for use as 
in-situ gelling systems. The gelling capacity was determined by 
placing a drop of the formula in a vial containing 2 ml of freshly 
prepared simulated tear fluid and visually assessing the gel 
formation and recording the time for gelation and the time taken for 
the gel formed to dissolve [19, 20]. 
Osmolality evaluation 
50μl of ophthalmic preparation was taken using a micropipette and 
placed in Eppendorf vials and placed in the osmometer Osmomato 30, 
Germany and the depression in freezing point was recorded in 
comparison with standard NaCl 1%W/V solution of 300mOsmol [21].  
Rheological studies  
Viscosity and rheological properties of in situ forming drug delivery 
systems is an important factor in determining residence time of the 
drug in the eye [22]. Viscosity determination was carried NDJ-5S 
using spindle 1. The angular velocity was increased gradually from 
6, 12, 30, to 60 rpm and then decreased backward. The viscosity of 
the formulations was measured in mPa. s. 
In vitro release studies 
In vitro release study of in situ gel solution is carried out by using 
dissolution apparatus type II paddle type, Copley UK. The 
formulation was placed in dialysis membrane 0.08 μm pore size, 
which was previously soaked in STF overnight. The dialysis 
membrane is tied to the paddle shaft and immersed in 300 ml [15] of 
STF pH7.4 [23] as a dissolution medium and it was rotated at 50 rpm 
[16], maintained at a temperature of 37±0.5 °C [24,25]. Samples of 
10 ml were withdrawn at regular intervals and replaced with an 
equal volume of fresh medium. The test was done in triplets and the 
mean result was plotted against time.  
Release kinetic analysis  
The release data were subjected to different mathematical models 
such as first order, Higuchi’s model, and Korsmeyer-Peppas model to 
evaluate the release mechanism of the drug from the gel, [26, 27]the 
criteria for selecting the most appropriate model was based on a 
goodness-of-fit test, according to the equations:  
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Fraction of drug released at time t  Korsmeyer Peppas rate 
constant time n release exponent  
Determination of drug content  
The drug content was determined by diluting 1 ml of the selected 
formula to 100 ml with freshly prepared STF pH 7.4. Samples were 
taken from different sites of the container. Then 1 ml was withdrawn 
and further diluted to 10 ml with STF. Naproxen concentration was 
then determined at the maximum wavelength using a UV-Visible 
spectrophotometer Cary, win UV Varian Australia. 
FT-IR studies 
The possibility of drug-excipients interactions was investigated by 
FTIR studies. The FTIR graph of pure drug and the excipients for 
selected formula were recorded using KBR pellets. [28] The in-situ gel 
formula was placed in a petri dish and allowed to dry and then studied.  
Ocular irritancy studies 
The modified Draize technique was designed for the ocular irritation 
potential of the ophthalmic product. [24] Ocular irritation studies of 
the filtered selected formula [by a Milli-pore-filter] were performed 
on three male rabbits weighing 1-2 kg. According to Draize test, an 
eye drop of 50 µl of the selected formula, which was filtered with a 
0.22μ Millipore filter, was placed in the lower cul-de-sac and 
irritancy was tested at the time interval of 1 hr., 24 h, 48 h, and 72 h 
after administration. The rabbits were observed periodically for 
redness, swelling and watering of the eye [21].   
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RESULTS AND DISCUSSION 
Physical evaluation parameters 
Appearance  
The prepared formulas were translucent, to clear dispersions. The 
haziness observed during preparation due to precipitation of HPMC 
at elevated temperature was found to disappear and the clarity was 
regained after overnight standing.  
pH 
The pH values of all formulations were found to be satisfactory in 
the range (4.9-6.2) as shown in table 2. The appropriate pH for NSAI 
ophthalmic drug preparation is between 6-8 to ensure solubility of 
the drug, [11] while pH dependent ocular in-situ gel must be lower 
than the ocular pH of 7.4 for sol to gel transformation due to the 
buffering action of the tear fluid. Also, non-neutralized CB gels are 
acidic in nature, therefore the pH of the formulas was around 6 
which are considered within the acceptable range for ocular 
formulation ranging between 5 and 7.4. [1]. The pH of the formulas 
was significantly dependent on the CB concertation (p<0.01). 
Gelling capacity measurement of the sol-gel transition 
The gradings for gelling capacity are shown in table 2. Formulations 
containing HPMC K40 [1.5%] showed excellent gelation [F3-F6-F9] 
and increasing the concentration of CB significantly improved the 
gelation time (p<0.01), while changing the HPMC grade to K100 for 
the same CB concentration greatly improved gelation capacity and 
time as compared to the K40 grade. F10, F11and F12. This may be 
due to an increase in molecular weight of the HPMC and also 
increasing the density of the hydrophobic methyl group in the higher 
molecular weight HPMC [29]. 
 
Table 2: pH Values and physical appearance and gelation capacity and sol-gel transition time of naproxen ocular in-situ gel 
Gelling capacity* Gelation time [min] Physical appearance pH Formulation 
- 1.5±0.5 Thin Transparent Liquid 5.1±0.12 F1 
+ 2.5±0.5 Transparent liquid 6.0±0.03 F2 
+++ 9±0.1 Transparent Gel 6.0±0.04 F3 
++ 4.5±0.5 Transparent Liquid 5.8±0.11 F4 
++ 11±0.5 Opaque Liquid 4.9±0.21 F5 
+++ 23±1.0 Translucent dispersion 5.8±0.03 F6 
++ 11±0.5 Thin Opaque Dispersion 5.9±0.07 F7 
++ 8±0.5 Opaque Dispersion 5.6±0.01 F8 
+++ 20.5±0.5 Opaque pourable dispersion 4.9±0.10 F9 
+++ 40±3.0 Translucent dispersion 5.6±0.02 F10 
+++ 26±2.0 Translucent gel 5.6±0.05 F11 
++++ 35±1.0 Very Thick gel 6.2±0.03 F12 
* Where: - No gelation, + Gel after few minutes, dissolve rapidly, ++ Immediate gelation, remain for few min, +++ Immediate gelation but for few 
extended periods, ** the results are expressed in mean±SD (n=3) 
 
Osmolality evaluation 
The prepared formulas showed depression of freezing point, 10 
folds that of isotonic solutions as seen in table 3. This helps the 
formulation, since, the colloidal osmolality of tears is twenty-fold 
less than that of the corneal stroma. Therefore; formulation with 
a high colloidal osmolality; oncotic pressure, [30] may be of 
value for damaged corneal epithelial cell, due to Donnan effect, 
to reduce corneal swelling [deturgescence occurs], leading to a 
return of normal cell physiology [31]; in conjugation with the 
NSAI, leading to a return of normal cell physiology [32]. 
 
Table 3: Osmolality of naproxen ocular in-situ gel 
Formula Depression in freezing point Δ °C Osmolality [mOsmol] 
1% NaCl 0.54 300 
F1 6.7±0.01 3526.32±5.263 
F2 6.4±0.02 3368.42±10.526 
F3 6.2±0.05 3263.16±26.316 
F4 6.3±0.05 3315.79±26.316 
F5 6.6±0.02 3473.68±10.526 
F6 6.1±0.04 3210.53±21.053 
F7 6.5±0.02 3421.05±10.526 
F8 6.4±0.03 3368.42±15.789 
F9 6.4±0.01 3368.42±5.263 
F10 6.4±0.02 3368.42±10.526 
F11 6.9±0.03 3631.58±15.789 
F12 6.5±0.05 3421.05±26.316 
F13 6.7±0.035 3526.32±18.421 
 The results are expressed in mean±SD (n=3) 
 
Rheological study  
The fluids having high viscosity under low shear rates and low 
viscosity under high shear rates are called as pseudo-plastic fluids; 
these are often preferred in ophthalmic preparations [33]. Since 
the ocular shear rate is very high, the mean blink rate at rest is 17 
blinks/min which increases during conversation to 26 blinks/min 
[34]. Also, during blinking the shearing force on the preparation is 
large. The higher the viscosity of the preparation, then more shear 
rate is needed (blinking), this will result in irritation. On the other 
hand, if the viscosity is too low it will give rise to excessive 
drainage. Fig. 1a and 1b shows the effect of increasing angular 
velocity on the viscosity for formulas (F1, F4, F7 and F100) at 
0.75% w/v of the hydrophilic polymer and for formulas (F2, F5, F8 
and F11) at 1% w/v of the hydrophilic polymer, respectively with 
increasing concentration of CB. All the formulas showed shear 
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thinning behaviour; characteristic of pseudo-plastic fluids, with no 
thixotropy. The pseudo-plastic property of the formulation is in 
favor of sustaining the drainage of the drug from the conjunctival 
sac of the eye [34]. The viscosity was dependent on the type and 
concentration polymer used [35], changing the type of HPMC 
grade affected the viscosity as seen in fig. 2. The viscosity 




Fig. 1a: The viscosity of naproxen ocular in-situ gel formulas at 0.75% of the hydrophilic polymer, in relation to the angular velocity at 
room temperature (n=3) 
 
 




Fig. 2: The viscosity versus angular velocity for F7 (HPMC K40) and F10(HPMC K100) for the same concentration of CB (0.7%) at room 
temperature (n=3) 
 
In vitro release studies 
The incorporation of the hydrophilic polymer (HPMC K40 or HPMC 
K100) with the acidic anionic polymer CB enhanced the consistency 
and modified the release [24] of naproxen.  
From fig. 3 it is obvious that formulas containing HPMC K40 (F1-F9) 
showed fast drug release that may be attributed to the lower 
viscosity of the polymer in comparison with HPMC K100 polymer. 
Also, the initial fast release of drug can be explained by the fact that 
eye drops are formulated in water and hence the polymer was 
completely hydrated, when they meet the simulated tear fluid and 
gelation occurs, a pre-hydrated matrix is formed in which hydration 
and water penetration no longer limit drug release leading to an 
apparent diffusion-controlled release [36]. 
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Fig. 3: The release profile of naproxen ocular in-situ gel formulas F1-F9 containing HPMC K40 in STF at 37 °C (n=3) 
 
Another factor that has an influence on the rate of drug release is the 
molecular weight of the polymer in the formulation. Since HPMC 
K100 molecular weight is higher than HPMC K40; therefore, the 
release is slower in these formulas F10, F11 and F13 as seen in fig. 4. 
 
 
Fig. 4: The release profile of naproxen ocular in-situ gel formulas F10-F11 F13 containing HPMC K100 in STF at 37 °C (n=3) 
 
The formulas which displayed the best gelation capacity [F9-F10-
F11] release are shown in fig. 5, F10 sustained the release of 
naproxen more than F9, and less than F11, this result may be 
potentiated by the rheological studies where the rate of drug release 
decrease when the viscosity increase, the pseudo-plastic property of 
these formulations may be in favor of sustaining the release of drug 
in the conjunctival sac of the eye. The results indicated that the 
formulation F-10 showed better release amongst all formulations. 
This may be due to the presence of a higher concentration of CB 
along with the appropriate concentration of HPMC K100. 
  
 
Fig. 5: The release profile of naproxen ocular in situ gel formulas with the best gelation time in STF at 37 °C (n=3) 
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Release kinetic analysis 
The in vitro release profiles were fitted to various kinetic models 
[table 4] to find the mechanism of drug release. Formulas [1-6], and 
F10 had a [n] value of less than 0.45; suggesting Fickian, first-order 
diffusion release. The release of drug from swelling matrices HPMC 
showed that the rate and amount of drug released was dependent on 
the active substance dissolution and diffusion rates, and but also 
from the “drug particle translocation” process. In the case of low 
solubility drugs, the solid particles of active substance were 
transported from the swelling front of the matrices to the eroding 
front of the gel layer. The particle displacement process was 
explained as a result of the spring-like action of macromolecular 
chains upon transition from glassy to the rubbery state of the 
polymer. The expansion of the polymer chains by relaxation led to 
movement of dissolved drug. The release mechanism continued to 
be a diffusion-controlled after the glassy core of the hydrated layer 
disappeared, as the dissolved drug was already in the system [37]. 
While F7-F9 and F11; exhibited a [n] value more than 0.45 meaning 
non Fickian diffusion[38]. In formulas F7-F9 the time needed for 
polymer swelling is longer than time needed for drug diffusion, due to 
the fact the higher concentration of CD in comparison with formulas F 
[1-6] for the same HPMC grade K40, and F11 for HPMC K100. 
 
Table 4: The release kinetic analysis of naproxen ocular in-situ gel 
Korsmeyer-peppas Higuchi First Order Formula 
 n R² K1 R² KH R² K1 
Fickian 0.314 0.9494 19.561 0.8436 8.408 0.9235 0.025 F1 
Fickian 0.336 0.9824 13.842 0.9038 6.577 0.7954 0.013 F2 
Fickian 0.350 0.9853 17.337 0.9224 8.782 0.9689 0.026 F3 
Fickian 0.334 0.9573 17.046 0.8778 8.021 0.9166 0.021 F4 
Fickian 0.405 0.9808 9.760 0.9594 6.345 0.8847 0012 F5 
Fickian 0.224 0.9618 29.987 0.7096 9.391 0.9744 0.040 F6 
Non-Fickian 0.641 0.9846 3.840 0.9586 7.339 0.9595 0.014 F7 
Non-Fickian 0.692 0.9794 2.746 0.9334 6.658 0.9242 0.911 F8 
Non-Fickian 0.459 0.9935 8.311 0.9900 6.882 0.9439 0.013 F9 
Fickian 0.384 0.9895 13.702 0.9151 8.073 0.9789 0.021 F10 
Non-Fickian 0.523 0.9833 8.084 0.8791  8.992 0.9041 0.023 F11 
 
Drug content 
The drug content of formula F10 [the selected formula] was 
found to 100%±2% in STF, F10 showed a uniform distribution of 
the drug in the ophthalmic formulations, according to USP 
dosage form criteria [39] 
FTIR study  
FT-IR spectrum of pure naproxen, the selected formula F10 and 
polymers used in the formula are shown in fig. 6. The spectral study 
showed that there was no significant change in the peaks of pure drug 
and the selected formula F10. Hence, no specific interaction was 
observed between the drug and the polymers used in the formulations. 
Infrared naproxen spectrum showed principal peaks at wavenumbers: 
3217 cm-1ⱱ [OH], 1720 cm-1ⱱ [C=O] of carboxylic acid group, 1610, 
1493,1454 cm-1are due to ⱱ [C=C] polycyclic aromatic structure, 1393, 
675 cm-1are due [OH] bending [40], also 1180, 1082 cm-1due ⱱ [C-O] of 
the ether group [28]. The same bands appear in the selected formula 
F10 [1724, 1606, 1392, 1113, 1063, 679 cm-1]  
It reveals there is no drug-excipient interaction. 
Ocular irritancy test 
In vivo eye irritation testing was carried out using F10. The 
formulations were found to be non-irritating with no ocular damage 
or abnormal clinical signs to the cornea, iris or conjunctivae 
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Fig. 6: FTIR spectrum of the selected formula F10 [A], Naproxen [B], carbomer CB [C], and HPMC K100 [D] 
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CONCLUSION 
The primary requirement of a successful controlled release product 
focuses on increasing patient compliance, which the in-situ gels offer. 
Exploitation of polymeric in situ gels for controlled release of drug 
provides several advantages over conventional dosage forms. Use of 
biodegradable and hydrophilic polymers for the in-situ gel formulations 
can make them more acceptable and excellent drug delivery systems.  
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